Loading clinical trials...
Loading clinical trials...
A Phase 3, 4-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-151 Cream 0.15% Administered QD in Subjects With Atopic Dermatitis
Conditions
Interventions
Roflumilast Cream 0.15%
Vehicle Cream
Locations
49
United States
Arcutis Clinical Site 57
Montgomery, Alabama, United States
Arcutis Clinical Site 34
Scottsdale, Arizona, United States
Arcutis Clinical Site 58
Little Rock, Arkansas, United States
Arcutis Clinical Site 40
Beverly Hills, California, United States
Arcutis Clinical Site 06
Encinitas, California, United States
Arcutis Clinical Site 52
Los Angeles, California, United States
Start Date
January 27, 2021
Primary Completion Date
August 30, 2022
Completion Date
August 30, 2022
Last Updated
October 9, 2024
NCT06004986
NCT06850311
NCT06454942
NCT05704205
NCT06469385
NCT03795506
Lead Sponsor
Arcutis Biotherapeutics, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions